Company and Stock Identity

How Koios Medical Connects to the Public Market

Company structure
Private company
Market access
No current public listing was verified.
Research focus
Koios holds four clearances in this site's FDA records, the newest dated 2 July 2026, all for software that assesses lesions suspicious for cancer. The company's own news page has posted nothing dated since 2023, so treat current customer counts and reading claims as unverified until the company supplies references. Ask for the breast and the thyroid evidence separately, because they are different exams.

Koios Medical's own site announced on 28 February 2023 that Mitsui and Co. invested in the company. No later ownership change was found when checked on 2026-10-10.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

No dated update is in the editorial file yet. Use the verified company sources below and check the profile verification date before relying on an older announcement.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: Koios sends job seekers to a hosted job board instead of listing role families on its own site, so the only way to see openings is that board.

Qualification signal: Ultrasound depends heavily on how the image was captured, so people who understand sonographer workflow count as much as model builders here.

Check current roles at Koios Medical. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Radiology leadership, pathology leadership, clinical informatics, imaging IT, patient safety, and procurement
Primary use case
Triage studies, flag findings, support image interpretation, and coordinate time-sensitive care
Typical deployment
Usually integrated with PACS, RIS, worklists, or digital pathology systems and monitored inside the clinical workflow

Evidence questions

  • Was the tool tested prospectively and independently on comparable equipment and patients?
  • What are sensitivity, specificity, false positive workload, and time-to-action effects?
  • How does performance vary by site, scanner, demographic subgroup, and disease prevalence?

Regulatory and workflow questions

  • Which FDA authorization covers the exact product version, modality, and intended use?
  • Who retains final clinical responsibility and how is disagreement with the AI handled?
  • What post-deployment monitoring and material update notification does the vendor provide?

Data and contract questions

  • Where are images and derived data processed and retained?
  • Which PACS, RIS, pathology, and EHR integrations are supported in production?
  • Can data be used for model improvement, and what controls govern secondary use?

Evidence and Regulation

FDA Clearances on Record

Koios Medical appears on 4 cleared products in the federal 510(k) record, across 1 device type.

A clearance means the FDA agreed the product is close enough to something already on the market to be sold for that use. It is not a finding that the product helps patients, and it is not a ranking against anything else on this page. A company is linked to an FDA clearance only when the 510(k) applicant name on the government record is confirmed by hand to be that same company, including former corporate names. Name similarity alone is never enough, and rejected matches are listed below with the reason.

What the Published Research Says About This Work

Independent studies on the work itself help separate category evidence from one company's claims.

First-Hand Sources